Jochem B Buil1,2, Roger J M Brüggemann2,3, Roeland E Wasmann2,3, Jan Zoll1,2, Jacques F Meis1,2,4, Willem J G Melchers1,2, Johan W Mouton1,5, Paul E Verweij1,2. 1. Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands. 2. Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands. 3. Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands. 4. Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. 5. Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands.
Abstract
INTRODUCTION: Isavuconazole is a new triazole approved for the treatment of invasive aspergillosis. We investigated isavuconazole MIC distributions, isavuconazole MIC correlations with those of other azoles and pharmacodynamics of isavuconazole in low-level resistant Aspergillus fumigatus isolates. METHODS: Isavuconazole, voriconazole, itraconazole and posaconazole susceptibility of 487 clinical A. fumigatus isolates was determined by EUCAST broth microdilution methodology. Using an in vivo estimation of the pharmacodynamic target and a previously published pharmacokinetic model, the probability of target attainment (PTA) was determined for a range of isavuconazole MICs using three dosing regimens (I, 200 mg once daily; II, 300 mg once daily; and III, 400 mg once daily). RESULTS: Two hundred and seventy-nine of 487 isolates were phenotypically WT based on epidemiological cut-offs of voriconazole, itraconazole and posaconazole. Twenty-five of 279 phenotypically WT isolates and 196 of 208 non-WT isolates were classified as isavuconazole resistant based on the EUCAST breakpoint of 1 mg/L. Isavuconazole MICs showed very high correlation with voriconazole MICs, but moderate and low correlation with itraconazole and posaconazole MICs. The PTA for isolates with an isavuconazole MIC of 1 mg/L was 92%-99% for 90% effective concentration (EC90) for the three dosing regimens. For isolates with an MIC of 2 mg/L the PTA decreased to 64%-92% for EC90. CONCLUSIONS: Our study indicated that isavuconazole and voriconazole MICs are highly correlated and that high-dose isavuconazole treatment might be an option in patients infected with an A. fumigatus isolate with an isavuconazole MIC of 2 mg/L.
INTRODUCTION: Isavuconazole is a new triazole approved for the treatment of invasive aspergillosis. We investigated isavuconazole MIC distributions, isavuconazole MIC correlations with those of other azoles and pharmacodynamics of isavuconazole in low-level resistant Aspergillus fumigatus isolates. METHODS: Isavuconazole, voriconazole, itraconazole and posaconazole susceptibility of 487 clinical A. fumigatus isolates was determined by EUCAST broth microdilution methodology. Using an in vivo estimation of the pharmacodynamic target and a previously published pharmacokinetic model, the probability of target attainment (PTA) was determined for a range of isavuconazole MICs using three dosing regimens (I, 200 mg once daily; II, 300 mg once daily; and III, 400 mg once daily). RESULTS: Two hundred and seventy-nine of 487 isolates were phenotypically WT based on epidemiological cut-offs of voriconazole, itraconazole and posaconazole. Twenty-five of 279 phenotypically WT isolates and 196 of 208 non-WT isolates were classified as isavuconazole resistant based on the EUCAST breakpoint of 1 mg/L. Isavuconazole MICs showed very high correlation with voriconazole MICs, but moderate and low correlation with itraconazole and posaconazole MICs. The PTA for isolates with an isavuconazole MIC of 1 mg/L was 92%-99% for 90% effective concentration (EC90) for the three dosing regimens. For isolates with an MIC of 2 mg/L the PTA decreased to 64%-92% for EC90. CONCLUSIONS: Our study indicated that isavuconazole and voriconazole MICs are highly correlated and that high-dose isavuconazole treatment might be an option in patients infected with an A. fumigatus isolate with an isavuconazole MIC of 2 mg/L.
Authors: A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl Journal: Stud Mycol Date: 2021-05-10 Impact factor: 16.097
Authors: Olga Rivero-Menendez; Juan Carlos Soto-Debran; Narda Medina; Jose Lucio; Emilia Mellado; Ana Alastruey-Izquierdo Journal: Antimicrob Agents Chemother Date: 2019-08-23 Impact factor: 5.191
Authors: Deborah E A Lockhart; Mathew Stanley; Olawale G Raimi; David A Robinson; Dominika Boldovjakova; Daniel R Squair; Andrew T Ferenbach; Wenxia Fang; Daan M F van Aalten Journal: J Biol Chem Date: 2020-04-27 Impact factor: 5.157
Authors: Michael A Pfaller; Paul R Rhomberg; Nathan P Wiederhold; Connie Gibas; Carmita Sanders; Hongxin Fan; James Mele; Laura L Kovanda; Mariana Castanheira Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191
Authors: Jeffrey D Jenks; Helmut Jf Salzer; Juergen Prattes; Robert Krause; Dieter Buchheidt; Martin Hoenigl Journal: Drug Des Devel Ther Date: 2018-04-30 Impact factor: 4.162